Improvements in drug development and clinical trial design have resulted in a wider range of treatment options for patients with advanced non-small cell lung cancer (NSCLC). Combination chemotherapy is the standard of care for medically fit patients. A variety of chemotherapeutic doublets, including nonplatinum combinations, with similar clinical activity are now available, allowing oncologists to match acceptable toxicity profiles to individual patients' comorbidities and preferences. Single-agent treatment of refractory or recurrent disease has been shown to improve survival and offer improved quality of life (QOL). For special patient populations, such as the elderly and patients with limited performance status (PS), treatment with single-agent chemotherapy results in modest survival benefits and combination chemotherapy may be appropriate for some of these patients.

中文翻译：

---

细胞毒性化学疗法治疗转移性或复发性非小细胞肺癌的研究进展。

药物开发和临床试验设计的改进为晚期非小细胞肺癌（NSCLC）患者提供了更多的治疗选择。联合化疗是适合医疗状况良好患者的标准治疗方法。现在可以使用具有相似临床活性的多种化学治疗双联体，包括非铂类组合，使肿瘤科医生可以将可接受的毒性谱与个别患者的合并症和偏爱相匹配。难治性或复发性疾病的单药治疗已显示可提高生存率并改善生活质量（QOL）。对于特殊的患者群体，例如老年人和表现状态有限（PS）的患者，